论文部分内容阅读
转化生长因子β(TGF-β)、血管内皮生长因子(VEGF)、白细胞介素10(IL-10)、环氧合酶(COX)、前列腺素(PG)E2等是卵巢癌细胞分泌的主要免疫抑制分子。这些分子可通过抑制抗原提呈细胞(APC)有效提呈肿瘤抗原,阻断T细胞、自然杀伤(NK)细胞和巨噬细胞等的抗瘤活性,促进肿瘤新生血管生成等机制,使肿瘤细胞得以逃避机体免疫监视而增殖和转移。这些免疫抑制分子在卵巢癌组织中的表达及其在患者体内的含量变化可望成为辅助疗效判断、观察预后的临床检测指标,为临床最佳治疗方案的选择提供理论依据,并可作为开发抗瘤药物的新靶点,为卵巢癌的生物治疗提供新思路。
Transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), interleukin 10 (IL-10), cyclooxygenase (COX), prostaglandin (PG) E2 are the main secreted by ovarian cancer cells Immunosuppressive molecules. These molecules can effectively inhibit tumor antigen presenting cells (APC), block the anti-tumor activity of T cells, natural killer (NK) cells and macrophages and promote tumor angiogenesis and other mechanisms, so that tumor cells To escape the proliferation of immune surveillance and proliferation. The expression of these immunosuppressive molecules in ovarian cancer tissue and its content in patients is expected to be adjuvant therapy to determine the prognosis of the clinical detection of indicators for the clinical best treatment options to provide a theoretical basis and can be used as a development of anti New targets of tumor drugs, provide new ideas for the biological treatment of ovarian cancer.